Key Laboratory of Optoelectronic Devices and Systems of Ministry of Education and Guangdong Province, Institute of Microscale Optoelectronics, and Otolaryngology Department and Biobank of the First Affiliated Hospital, Shenzhen Second People's Hospital, Health Science Center, Shenzhen University, Shenzhen 518060, P. R. China.
Chem Soc Rev. 2021 Aug 21;50(16):9152-9201. doi: 10.1039/d0cs01370f. Epub 2021 Jul 5.
Photodynamic therapy (PDT) has been extensively investigated for decades for tumor treatment because of its non-invasiveness, spatiotemporal selectivity, lower side-effects, and immune activation ability. It can be a promising treatment modality in several medical fields, including oncology, immunology, urology, dermatology, ophthalmology, cardiology, pneumology, and dentistry. Nevertheless, the clinical application of PDT is largely restricted by the drawbacks of traditional photosensitizers, limited tissue penetrability of light, inefficient induction of tumor cell death, tumor resistance to the therapy, and the severe pain induced by the therapy. Recently, various photosensitizer formulations and therapy strategies have been developed to overcome these barriers. Significantly, the introduction of nanomaterials in PDT, as carriers or photosensitizers, may overcome the drawbacks of traditional photosensitizers. Based on this, nanocomposites excited by various light sources are applied in the PDT of deep-seated tumors. Modulation of cell death pathways with co-delivered reagents promotes PDT induced tumor cell death. Relief of tumor resistance to PDT with combined therapy strategies further promotes tumor inhibition. Also, the optimization of photosensitizer formulations and therapy procedures reduces pain in PDT. Here, a systematic summary of recent advances in the fabrication of photosensitizers and the design of therapy strategies to overcome barriers in PDT is presented. Several aspects important for the clinical application of PDT in cancer treatment are also discussed.
光动力疗法(PDT)因其非侵入性、时空选择性、较低的副作用和免疫激活能力,已被广泛研究了数十年,用于肿瘤治疗。它可以成为多个医学领域的一种有前途的治疗方式,包括肿瘤学、免疫学、泌尿科、皮肤科、眼科、心脏病学、肺病学和牙科。然而,传统光敏剂的缺点、光的组织穿透性有限、肿瘤细胞死亡诱导效率低、肿瘤对治疗的耐药性以及治疗引起的严重疼痛等因素,极大地限制了 PDT 的临床应用。最近,已经开发了各种光敏剂制剂和治疗策略来克服这些障碍。值得注意的是,将纳米材料引入 PDT 作为载体或光敏剂,可能会克服传统光敏剂的缺点。在此基础上,各种光源激发的纳米复合材料被应用于深部肿瘤的 PDT 治疗。通过共递试剂来调节细胞死亡途径,促进 PDT 诱导的肿瘤细胞死亡。联合治疗策略缓解肿瘤对 PDT 的耐药性,进一步促进肿瘤抑制。此外,通过优化光敏剂制剂和治疗程序,减轻 PDT 中的疼痛。本文系统总结了近年来在光敏剂的制备和治疗策略的设计方面克服 PDT 障碍的进展。还讨论了 PDT 在癌症治疗中临床应用的几个重要方面。